Strontium-89
Intended use
Sr-89 is among the most effective modern therapeutic agents utilized for palliative treatment of patients with metastatic tumors in the prostate, breast, kidneys, and lungs.
Sr-89 is also employed as an alternative method (or as a supplement to external beam therapy) for the management of pain syndrome in bone cancer.
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: 89Strontium solution as a chloride
Half-life period: 50.5 days
Concentrations, mg/ml: 10.9−22.6
Concentrations of Radioactive Impurities (relative to 89Sr activity), %:
90Sr: ≤2.0×10−4
Other Radionuclides: ≤1.0×10−3
Other γ-emitting Impurities: ≤0.35
Radioactive concentrations, MBq/ml: 33.3−40.7 on production date
Sr-89 is among the most effective modern therapeutic agents utilized for palliative treatment of patients with metastatic tumors in the prostate, breast, kidneys, and lungs.
Sr-89 is also employed as an alternative method (or as a supplement to external beam therapy) for the management of pain syndrome in bone cancer.
Grade:
1. Non-carrier added radionuclide;
2. GMP product;
3. Tested for sterility and bacterial endotoxins.
Chemical form: 89Strontium solution as a chloride
Half-life period: 50.5 days
Concentrations, mg/ml: 10.9−22.6
Concentrations of Radioactive Impurities (relative to 89Sr activity), %:
90Sr: ≤2.0×10−4
Other Radionuclides: ≤1.0×10−3
Other γ-emitting Impurities: ≤0.35
Radioactive concentrations, MBq/ml: 33.3−40.7 on production date
Other products
